Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 84

1.

Rational Construction of Compact de Novo-Designed Biliverdin-Binding Proteins.

Sheehan MM, Magaraci MS, Kuznetsov IA, Mancini JA, Kodali G, Moser CC, Dutton PL, Chow BY.

Biochemistry. 2018 Nov 28. doi: 10.1021/acs.biochem.8b01076. [Epub ahead of print]

2.

Community, Context, and Coping: How Social Connections Influence Coping and Well-Being for Military Members and Their Spouses.

O'Neal CW, Richardson EW, Mancini JA.

Fam Process. 2018 Oct 7. doi: 10.1111/famp.12395. [Epub ahead of print]

PMID:
30294836
3.

A synthetic biological quantum optical system.

Lishchuk A, Kodali G, Mancini JA, Broadbent M, Darroch B, Mass OA, Nabok A, Dutton PL, Hunter CN, Törmä P, Leggett GJ.

Nanoscale. 2018 Jul 13;10(27):13064-13073. doi: 10.1039/c8nr02144a.

4.

De novo synthetic biliprotein design, assembly and excitation energy transfer.

Mancini JA, Sheehan M, Kodali G, Chow BY, Bryant DA, Dutton PL, Moser CC.

J R Soc Interface. 2018 Apr;15(141). pii: 20180021. doi: 10.1098/rsif.2018.0021.

PMID:
29618529
5.

The Importance of Parents' Community Connections for Adolescent Well-being: An Examination of Military Families.

O'Neal CW, Mallette JK, Mancini JA.

Am J Community Psychol. 2018 Mar;61(1-2):204-217. doi: 10.1002/ajcp.12222. Epub 2018 Feb 5.

PMID:
29400402
6.

Resilient family processes, personal reintegration, and subjective well-being outcomes for military personnel and their family members.

Clark MA, O'Neal CW, Conley KM, Mancini JA.

Am J Orthopsychiatry. 2018;88(1):99-111. doi: 10.1037/ort0000278. Epub 2017 Jun 15.

PMID:
28617007
7.

Design and engineering of water-soluble light-harvesting protein maquettes.

Kodali G, Mancini JA, Solomon LA, Episova TV, Roach N, Hobbs CJ, Wagner P, Mass OA, Aravindu K, Barnsley JE, Gordon KC, Officer DL, Dutton PL, Moser CC.

Chem Sci. 2017 Jan 1;8(1):316-324. doi: 10.1039/C6SC02417C. Epub 2016 Aug 17.

8.

Multi-step excitation energy transfer engineered in genetic fusions of natural and synthetic light-harvesting proteins.

Mancini JA, Kodali G, Jiang J, Reddy KR, Lindsey JS, Bryant DA, Dutton PL, Moser CC.

J R Soc Interface. 2017 Feb;14(127). pii: 20160896. doi: 10.1098/rsif.2016.0896.

9.

Contextualizing the Psychosocial Well-being of Military Members and Their Partners: The Importance of Community and Relationship Provisions.

O'Neal CW, Mancini JA, DeGraff A.

Am J Community Psychol. 2016 Dec;58(3-4):477-487. doi: 10.1002/ajcp.12097. Epub 2016 Nov 3.

PMID:
27808420
10.

Social stressors, coping behaviors, and depressive symptoms: A latent profile analysis of adolescents in military families.

Okafor E, Lucier-Greer M, Mancini JA.

J Adolesc. 2016 Aug;51:133-43. doi: 10.1016/j.adolescence.2016.05.010. Epub 2016 Jun 30.

PMID:
27372508
11.

The Willingness of Military Members to Seek Help: The Role of Social Involvement and Social Responsibility.

Bowen GL, Jensen TM, Martin JA, Mancini JA.

Am J Community Psychol. 2016 Mar;57(1-2):203-15. doi: 10.1002/ajcp.12030.

PMID:
27217323
12.

Parents' early life stressful experiences, their present well-being, and that of their children.

O'Neal CW, Richardson EW, Mancini JA, Grimsley RN.

Am J Orthopsychiatry. 2016;86(4):425-435. doi: 10.1037/ort0000140. Epub 2016 Apr 14.

PMID:
27078050
13.

Family Relational Health, Psychological Resources, and Health Behaviors: A Dyadic Study of Military Couples.

O'Neal CW, Lucier-Greer M, Mancini JA, Ferraro AJ, Ross DB.

Mil Med. 2016 Feb;181(2):152-60. doi: 10.7205/MILMED-D-14-00740.

PMID:
26837084
14.

Adolescent mental health and academic functioning: empirical support for contrasting models of risk and vulnerability.

Lucier-Greer M, O'Neal CW, Arnold AL, Mancini JA, Wickrama KK.

Mil Med. 2014 Nov;179(11):1279-87. doi: 10.7205/MILMED-D-14-00090.

PMID:
25373055
15.

Constructing a man-made c-type cytochrome maquette in vivo: electron transfer, oxygen transport and conversion to a photoactive light harvesting maquette.

Anderson JLR, Armstrong CT, Kodali G, Lichtenstein BR, Watkins DW, Mancini JA, Boyle AL, Farid TA, Crump MP, Moser CC, Dutton PL.

Chem Sci. 2014 Feb 1;5(2):507-514. doi: 10.1039/C3SC52019F. Epub 2013 Oct 31.

16.

Heterogeneity in multidimensional health trajectories of late old years and socioeconomic stratification: a latent trajectory class analysis.

Wickrama KK, Mancini JA, Kwag K, Kwon J.

J Gerontol B Psychol Sci Soc Sci. 2013 Mar;68(2):290-7. doi: 10.1093/geronb/gbs111. Epub 2012 Nov 29.

PMID:
23197341
17.

GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity.

Xu J, Morinaga H, Oh D, Li P, Chen A, Talukdar S, Mamane Y, Mancini JA, Nawrocki AR, Lazarowski E, Olefsky JM, Kim JJ.

J Immunol. 2012 Aug 15;189(4):1992-9. doi: 10.4049/jimmunol.1103207. Epub 2012 Jul 9. Erratum in: J Immunol. 2013 Feb 1;190(3):1380. Mamane, Yaël [added]; Mancini, Joseph A [added]; Nawrocki, Andrea R [added].

18.

Engineering oxidoreductases: maquette proteins designed from scratch.

Lichtenstein BR, Farid TA, Kodali G, Solomon LA, Anderson JL, Sheehan MM, Ennist NM, Fry BA, Chobot SE, Bialas C, Mancini JA, Armstrong CT, Zhao Z, Esipova TV, Snell D, Vinogradov SA, Discher BM, Moser CC, Dutton PL.

Biochem Soc Trans. 2012 Jun 1;40(3):561-6. doi: 10.1042/BST20120067. Review.

19.

Cortactin activation by FVIIa/tissue factor and PAR2 promotes endothelial cell migration.

Zhu T, Mancini JA, Sapieha P, Yang C, Joyal JS, Honoré JC, Leduc M, Zaniolo K, Hardy P, Shao Z, Fan L, Hou X, Rivard GE, Chemtob S.

Am J Physiol Regul Integr Comp Physiol. 2011 Mar;300(3):R577-85. doi: 10.1152/ajpregu.00137.2010. Epub 2010 Dec 15.

20.

Sustained hypercapnia induces cerebral microvascular degeneration in the immature brain through induction of nitrative stress.

Honoré JC, Kooli A, Hou X, Hamel D, Rivera JC, Picard E, Hardy P, Tremblay S, Varma DR, Jankov RP, Mancini JA, Balazy M, Chemtob S.

Am J Physiol Regul Integr Comp Physiol. 2010 Jun;298(6):R1522-30. doi: 10.1152/ajpregu.00807.2009. Epub 2010 Mar 31.

21.

Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.

Lacombe P, Chauret N, Claveau D, Day S, Deschênes D, Dubé D, Gallant M, Girard Y, Huang Z, Laliberté F, Lévesque JF, Liu S, Macdonald D, Mancini JA, Masson P, Nicholson DW, Nicoll-Griffith DA, Salem M, Styhler A, Young RN.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5266-9. doi: 10.1016/j.bmcl.2009.03.105. Epub 2009 Mar 26.

PMID:
19640717
22.

The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation.

Mamane Y, Chung Chan C, Lavallee G, Morin N, Xu LJ, Huang J, Gordon R, Thomas W, Lamb J, Schadt EE, Kennedy BP, Mancini JA.

Diabetes. 2009 Sep;58(9):2006-17. doi: 10.2337/db09-0323. Epub 2009 Jul 6.

23.

Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.

Guay D, Boulet L, Friesen RW, Girard M, Hamel P, Huang Z, Laliberté F, Laliberté S, Mancini JA, Muise E, Pon D, Styhler A.

Bioorg Med Chem Lett. 2008 Oct 15;18(20):5554-8. doi: 10.1016/j.bmcl.2008.09.009. Epub 2008 Sep 6.

PMID:
18835163
24.

Phosphodiesterase 3 and 4 comprise the major cAMP metabolizing enzymes responsible for insulin secretion in INS-1 (832/13) cells and rat islets.

Waddleton D, Wu W, Feng Y, Thompson C, Wu M, Zhou YP, Howard A, Thornberry N, Li J, Mancini JA.

Biochem Pharmacol. 2008 Oct 1;76(7):884-93. doi: 10.1016/j.bcp.2008.07.025. Epub 2008 Jul 26.

PMID:
18706893
25.

Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.

Friesen RW, Mancini JA.

J Med Chem. 2008 Jul 24;51(14):4059-67. doi: 10.1021/jm800197b. Epub 2008 May 7. No abstract available.

PMID:
18459759
26.

L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.

Huang Z, Dias R, Jones T, Liu S, Styhler A, Claveau D, Otu F, Ng K, Laliberte F, Zhang L, Goetghebeur P, Abraham WM, Macdonald D, Dubé D, Gallant M, Lacombe P, Girard Y, Young RN, Turner MJ, Nicholson DW, Mancini JA.

Biochem Pharmacol. 2007 Jun 15;73(12):1971-81. Epub 2007 Mar 16.

PMID:
17428447
27.

Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.

Huang Z, Mancini JA.

Curr Med Chem. 2006;13(27):3253-62. Review.

PMID:
17168849
28.
29.

Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.

Lacombe P, Deschênes D, Dubé D, Dubé L, Gallant M, Macdonald D, Mastracchio A, Perrier H, Charleson S, Huang Z, Laliberté F, Liu S, Mancini JA, Masson P, Salem M, Styhler A, Girard Y.

Bioorg Med Chem Lett. 2006 May 15;16(10):2608-12. Epub 2006 Mar 3.

PMID:
16516471
30.

Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886.

Riendeau D, Aspiotis R, Ethier D, Gareau Y, Grimm EL, Guay J, Guiral S, Juteau H, Mancini JA, Méthot N, Rubin J, Friesen RW.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3352-5.

PMID:
15953724
31.

Intracellular-specific colocalization of prostaglandin E2 synthases and cyclooxygenases in the brain.

Vazquez-Tello A, Fan L, Hou X, Joyal JS, Mancini JA, Quiniou C, Clyman RI, Gobeil F Jr, Varma DR, Chemtob S.

Am J Physiol Regul Integr Comp Physiol. 2004 Nov;287(5):R1155-63. Epub 2004 Jul 29.

33.

Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile.

Boulet L, Ouellet M, Bateman KP, Ethier D, Percival MD, Riendeau D, Mancini JA, Méthot N.

J Biol Chem. 2004 May 28;279(22):23229-37. Epub 2004 Mar 11.

34.

Evaluation of loxoprofen and its alcohol metabolites for potency and selectivity of inhibition of cyclooxygenase-2.

Riendeau D, Salem M, Styhler A, Ouellet M, Mancini JA, Li CS.

Bioorg Med Chem Lett. 2004 Mar 8;14(5):1201-3.

PMID:
14980665
35.

Expression, purification and characterization of recombinant human microsomal PGE2 synthase-1.

Ouellet M, Pen A, Ear PH, Falgueyret JP, LeRiche TG, Mancini JA, Riendeau D, Percival MD.

Adv Exp Med Biol. 2003;525:113-6. No abstract available.

PMID:
12751747
36.

Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.

Ducharme Y, Friesen RW, Blouin M, Côté B, Dubé D, Ethier D, Frenette R, Laliberté F, Mancini JA, Masson P, Styhler A, Young RN, Girard Y.

Bioorg Med Chem Lett. 2003 Jun 2;13(11):1923-6.

PMID:
12749899
37.
38.

Purification and characterization of recombinant microsomal prostaglandin E synthase-1.

Ouellet M, Falgueyret JP, Ear PH, Pen A, Mancini JA, Riendeau D, Percival MD.

Protein Expr Purif. 2002 Dec;26(3):489-95.

PMID:
12460774
39.

Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.

Muise ES, Chute IC, Claveau D, Masson P, Boulet L, Tkalec L, Pon DJ, Girard Y, Frenette R, Mancini JA.

Biochem Pharmacol. 2002 Apr 15;63(8):1527-35.

PMID:
11996895
40.
41.

Urogenital distribution of a mouse membrane-associated prostaglandin E(2) synthase.

Guan Y, Zhang Y, Schneider A, Riendeau D, Mancini JA, Davis L, Kömhoff M, Breyer RM, Breyer MD.

Am J Physiol Renal Physiol. 2001 Dec;281(6):F1173-7.

42.

Cloning, expression, and up-regulation of inducible rat prostaglandin e synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis.

Mancini JA, Blood K, Guay J, Gordon R, Claveau D, Chan CC, Riendeau D.

J Biol Chem. 2001 Feb 9;276(6):4469-75. Epub 2000 Nov 6.

43.

Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides.

Guay J, Falgueyret JP, Ducret A, Percival MD, Mancini JA.

Eur J Biochem. 2000 Oct;267(20):6311-8.

44.

Expression, maturation, and rhodamine-based fluorescence assay of human cathepsin K expressed in CHO cells.

Claveau D, Riendeau D, Mancini JA.

Biochem Pharmacol. 2000 Sep 15;60(6):759-69.

PMID:
10930530
45.

Cloning and expression of rhesus monkey cathepsin K.

Guay J, Riendeau D, Mancini JA.

Bone. 1999 Aug;25(2):205-9.

PMID:
10456386
47.

Structural characterization of the covalent attachment of leukotriene A3 to leukotriene A4 hydrolase.

Mancini JA, Waugh RJ, Thompson JA, Evans JF, Belley M, Zamboni R, Murphy RC.

Arch Biochem Biophys. 1998 Jun 1;354(1):117-24.

PMID:
9633605
48.
49.

The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs.

Greig GM, Francis DA, Falgueyret JP, Ouellet M, Percival MD, Roy P, Bayly C, Mancini JA, O'Neill GP.

Mol Pharmacol. 1997 Nov;52(5):829-38.

50.

Characterization of microsomal GST-II by western blot and identification of a novel LTC4 isomer.

Jakobsson PJ, Scoggan KA, Yergey J, Mancini JA, Ford-Hutchinson AW.

J Lipid Mediat Cell Signal. 1997 Sep;17(1):15-9.

PMID:
9302651
51.

Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities.

Jakobsson PJ, Mancini JA, Riendeau D, Ford-Hutchinson AW.

J Biol Chem. 1997 Sep 5;272(36):22934-9.

52.

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al.

Br J Pharmacol. 1997 May;121(1):105-17.

53.
54.

Altered sensitivity of aspirin-acetylated prostaglandin G/H synthase-2 to inhibition by nonsteroidal anti-inflammatory drugs.

Mancini JA, Vickers PJ, O'Neill GP, Boily C, Falgueyret JP, Riendeau D.

Mol Pharmacol. 1997 Jan;51(1):52-60.

56.

Colocalization of cytosolic phospholipase A2, 5-lipoxygenase, and 5-lipoxygenase-activating protein at the nuclear membrane of A23187-stimulated human neutrophils.

Pouliot M, McDonald PP, Krump E, Mancini JA, McColl SR, Weech PK, Borgeat P.

Eur J Biochem. 1996 May 15;238(1):250-8.

57.
58.

Cloning and characterization of the human leukotriene A4 hydrolase gene.

Mancini JA, Evans JF.

Eur J Biochem. 1995 Jul 1;231(1):65-71.

59.

Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S.

Cancer Res. 1995 Jun 15;55(12):2556-9.

60.

Selective inhibitors of COX-2.

O'Neill GP, Kennedy BP, Mancini JA, Kargman S, Ouellet M, Yergey J, Falgueyret JP, Cromlish WA, Payette P, Chan CC, et al.

Agents Actions Suppl. 1995;46:159-68. Review.

PMID:
7610986
61.
62.

Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid.

O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret JP, Abramovitz M, Kennedy BP, Ouellet M, Cromlish W, et al.

Mol Pharmacol. 1994 Feb;45(2):245-54.

PMID:
8114674
63.

The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein.

Mancini JA, Coppolino MG, Klassen JH, Charleson S, Vickers PJ.

Life Sci. 1994;54(9):PL137-42.

PMID:
8114608
65.

5-Lipoxygenase activity in the human pancreas.

Mancini JA, Li C, Vickers PJ.

J Lipid Mediat. 1993 Nov;8(3):145-50.

PMID:
8268460
66.

Leukotriene synthesis in U937 cells expressing recombinant 5-lipoxygenase.

Kargman S, Rousseau P, Reid GK, Rouzer CA, Mancini JA, Rands E, Dixon RA, Diehl RE, Léveillé C, Nathaniel D, et al.

J Lipid Mediat. 1993 May;7(1):31-45.

PMID:
8358023
67.

5-lipoxygenase-activating protein is an arachidonate binding protein.

Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers PJ.

FEBS Lett. 1993 Mar 8;318(3):277-81.

68.

Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors.

Vickers PJ, Adam M, Charleson S, Abramovitz M, O'Neill G, Mancini JA.

J Lipid Mediat. 1993 Mar-Apr;6(1-3):31-42.

PMID:
8357989
69.

Cross-species comparison of 5-lipoxygenase-activating protein.

Vickers PJ, O'Neill GP, Mancini JA, Charleson S, Abramovitz M.

Mol Pharmacol. 1992 Dec;42(6):1014-9.

PMID:
1480129
70.

Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors.

Vickers PJ, Adam M, Charleson S, Coppolino MG, Evans JF, Mancini JA.

Mol Pharmacol. 1992 Jul;42(1):94-102.

PMID:
1635556
71.

Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.

Charleson S, Prasit P, Léger S, Gillard JW, Vickers PJ, Mancini JA, Charleson P, Guay J, Ford-Hutchinson AW, Evans JF.

Mol Pharmacol. 1992 May;41(5):873-9.

PMID:
1588922
72.

5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.

Mancini JA, Prasit P, Coppolino MG, Charleson P, Leger S, Evans JF, Gillard JW, Vickers PJ.

Mol Pharmacol. 1992 Feb;41(2):267-72.

PMID:
1538707
73.

Social provisions in adulthood: concept and measurement in close relationships.

Mancini JA, Blieszner R.

J Gerontol. 1992 Jan;47(1):P14-20.

PMID:
1730853
74.

5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.

Evans JF, Lévillé C, Mancini JA, Prasit P, Thérien M, Zamboni R, Gauthier JY, Fortin R, Charleson P, MacIntyre DE, et al.

Mol Pharmacol. 1991 Jul;40(1):22-7.

PMID:
1857337
75.

Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis.

Reid GK, Kargman S, Vickers PJ, Mancini JA, Léveillé C, Ethier D, Miller DK, Gillard JW, Dixon RA, Evans JF.

J Biol Chem. 1990 Nov 15;265(32):19818-23.

76.

Identification and isolation of a membrane protein necessary for leukotriene production.

Miller DK, Gillard JW, Vickers PJ, Sadowski S, Léveillé C, Mancini JA, Charleson P, Dixon RA, Ford-Hutchinson AW, Fortin R, et al.

Nature. 1990 Jan 18;343(6255):278-81.

PMID:
2300172
77.

Cloning and expression of the Photobacterium phosphoreum luminescence system demonstrates a unique lux gene organization.

Mancini JA, Boylan M, Soly RR, Graham AF, Meighen EA.

J Biol Chem. 1988 Oct 5;263(28):14308-14.

78.

A new lux gene in bioluminescent bacteria codes for a protein homologous to the bacterial luciferase subunits.

Soly RR, Mancini JA, Ferri SR, Boylan M, Meighen EA.

Biochem Biophys Res Commun. 1988 Aug 30;155(1):351-8.

PMID:
3415691
79.

Dimensions of health and their importance for morale in old age: a multivariate examination.

Mancini JA, Quinn WH.

J Community Health. 1981 Winter;7(2):118-28.

PMID:
7328196
80.

Life satisfaction among middle-aged adults: a research note.

Mancini JA.

Long Term Care Health Serv Adm Q. 1980 Winter;4(4):290-5. No abstract available.

PMID:
10249088
81.

Situational influences on leisure satisfaction and morale in old age.

Mancini JA, Orthner DK.

J Am Geriatr Soc. 1980 Oct;28(10):466-71.

PMID:
7419848
82.
83.

Family relationships and morale among people 65 years of age and older.

Mancini JA.

Am J Orthopsychiatry. 1979 Apr;49(2):292-300. doi: 10.1111/j.1939-0025.1979.tb02610.x.

PMID:
434123
84.

Supplemental Content

Loading ...
Support Center